Wie hoch ist der Preis für Medigene AG (MDG1)

Preis für Medigene AG (MDG1) ist $0.14942078

Wie hoch ist die Marktkapitalisierung für Medigene AG (MDG1)

Marktkapitalisierung für Medigene AG (MDG1) ist $3.86M

Medigene AG (MDG1) KUV

Medigene AG is a German biotechnology company primarily focused on innovating T cell immunotherapies to treat various cancers. Their developmental pipeline includes personalized T cell therapies, particularly T cell receptor-modified T cells, which are progressing through clinical stages to tackle significant unmet medical requirements. Additionally, the firm researches dendritic cell vaccines and T cell-specific monoclonal antibodies. Outside of its oncology efforts, Medigene is actively engaged in developing and bringing to market RhuDex for uses within hepatology and gastroenterology. A key strategic alliance exists with 2seventy bio, Inc., centered on advancing T cell receptors. The company also maintains research collaborations with the Université de Montréal and Cytovant Sciences Co. Ltd., investigating new cancer antigens for immunotherapy applications. Medigene's global presence encompasses operations across Europe, the United States, Asia, and various other international territories. Founded in 1994, the company's headquarters are located in Munich, Germany.

Jahr	P/S-Verhältnis	ändert
2026 (TTM)	0.33	-94.44%
2023	5.86	270.74%
2022	1.58	-76.40%
2021	6.70	-37.67%
2020	10.75	15.55%
2019	9.30	-81.25%
2018	49.61	-30.09%
2017	70.97	-38.41%
2016	115.23	29.31%
2015	89.11	1,204.14%
2014	6.83	-18.93%
2013	8.43	-29.80%
2012	12.01	-23.25%
2011	15.64	-52.41%
2010	32.87	915.33%
2009	3.24	-25.83%
2008	4.36	-43.78%
2007	7.76	51.85%
2006	5.11	-35.56%
2005	7.93	-16.62%
2004	9.52	0.00%

Jahr

P/S-Verhältnis

ändert

2026 (TTM)

0.33

-94.44%

2023

5.86

270.74%

2022

1.58

-76.40%

2021

6.70

-37.67%

2020

10.75

15.55%

2019

9.30

-81.25%

2018

49.61

-30.09%

2017

70.97

-38.41%

2016

115.23

29.31%

2015

89.11

1,204.14%

2014

6.83

-18.93%

2013

8.43

-29.80%

2012

12.01

-23.25%

2011

15.64

-52.41%

2010

32.87

915.33%

2009

3.24

-25.83%

2008

4.36

-43.78%

2007

7.76

51.85%

2006

5.11

-35.56%

2005

7.93

-16.62%

2004

9.52

0.00%

Unternehmen	P/S-Verhältnis	P/S-Verhältnis-Differenz	Land
Vertex Pharmaceuticals Incorporated VRTX.US	10.17	3,018.00%	US
Argenx SE ARGX.US	10.13	3,006.19%	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	4.74	1,354.31%	BE

Unternehmen

P/S-Verhältnis

P/S-Verhältnis-Differenz

Land